Close the acquisition of Inari Medical, Inc. by end of first quarter
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2025
- Due
- 31 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is anticipated to close by the end of the first quarter of 2025, subject to customary closing conditions.”
What we found
Evidence strength A What the grades mean
The Q1 2025 10-Q says the Neurovascular business was renamed Vascular due to the Inari acquisition in the first quarter, and Inari liabilities were assumed in Q1, implying closing by quarter-end.
-
A Stryker Corporation 10-Q filed 2025-05-02
“In the first quarter 2025 we changed the name of our Neurovascular business to Vascular due the acquisition of Inari Medical, Inc. (Inari).” ✓ confirmed on the page
-
A Stryker Corporation 10-Q filed 2025-05-02
“In the three months 2025 we assumed contingent consideration liabilities with a fair value of $90 related to previous acquisitions made by Inari Medical Inc. (Inari).” ✓ confirmed on the page
Market reaction: the shares moved +0.9% against the S&P 500 over the three sessions around the disclosure (1 May 2025 to 6 May 2025). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -31 days
- 2 versions
-
Version 1 · original · stated 7 Jan 2025
Deadline 31 Mar 2025 (“by the end of the first quarter of 2025”) · wording expected
-
Version 2 · stated 28 Jan 2025
Deadline 28 Feb 2025 (“toward the end of February”) · wording expected
“we anticipate closing this transaction toward the end of February”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Inari Medical, Inc.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to customary closing conditions; minimum tender of a majority of outstanding Inari shares; expiration or termination of Hart-Scott-Rodino waiting period
- Depends on
- Regulatory, Shareholder, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Stryker Corporation? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SYK-006376 · Corrections policy